2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of ... suboptimal response to autologous stem cell transplant. The Cambridge, Mass., company said it expects the move ...

CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Since cutting the ribbon on its inaugural commercial-scale Smart Factory in Bridgewater earlier this year, the San ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

Bristol-Myers Squibb Co’s Profitability and Valuation Ratios Bristol-Myers Squibb Co’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 17.58% ...

Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

Bristol Myers Squibb has signed a lease for just under 50,000 square ... feet on George Road in a suburban office complex ...

Carrick Group Limited, a Bermuda-based international non-life legacy insurer specialising in reinsurance and run-off ...

The latest trading session saw Bristol Myers Squibb (BMY) ending at $49.49, denoting a -1% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.03%. At the same time, ...